# **Appendix 3B**

### New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

Atlas Pearls and Perfumes Ltd

ABN

32 009	220	053
--------	-----	-----

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	<ol> <li>Fully paid ordinary shares.</li> <li>Unlisted options.</li> </ol>
		-
2	Number of <sup>+</sup> securities issued or to be issued (if known) or	1. 1,344,179 fully paid ordinary shares.
	maximum number which may be issued	2. 1,336,179 unlisted options.
3	Principal terms of the +securities (eg, if options, exercise price	1. Fully paid ordinary shares.
	and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if +convertible	2. Unlisted options exercisable at \$0.05 each on or before 29 January 2014.
	securities, the conversion price and dates for conversion)	

<sup>+</sup> See chapter 19 for defined terms.

4	<ul> <li>Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?</li> <li>If the additional securities do not rank equally, please state: <ul> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> </li> </ul>	<ol> <li>Yes - fully paid ordinary shares.</li> <li>No – unlisted options. Shares issued on exercise of the options will rank equally with existing quoted fully paid ordinary shares.</li> </ol>
5	Issue price or consideration	<ol> <li>Fully paid ordinary shares - \$0.05 per share.</li> <li>Unlisted options - nil, free options attaching to shortfall shares issued on 17 April 2013 under the Prospectus dated 16 November 2012.</li> </ol>
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ol> <li>Issue of (i) 8,000 fully paid ordinary shares on exercise of 8,000 unlisted options exercisable at \$0.05 each, on or before 29 January 2014 and (ii) 1,336,179 fully paid ordinary shares as placement of the shortfall from the Company's non-renounceable entitlements offer that closed on 18 January 2013.</li> <li>Issue of free attaching options to 1,336,179 fully paid ordinary shares issued on 17 April 2013 as placement of the shortfall from the Company's non-renounceable entitlements offer that closed on 18 January 2013.</li> </ol>
ба	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the <sup>+</sup>securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	No

- 6b The date the security holder resolution under rule 7.1A was passed
- Number of +securities issued 6c without security holder approval under rule 7.1
- 6d Number of *+*securities issued with security holder approval under rule 7.1A
- Number of *+*securities issued 6e with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of securities issued under an exception in rule 7.2
- If securities issued under rule 6g 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to **ASX Market Announcements**
- Calculate the entity's remaining 6i issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- Dates of entering <sup>+</sup>securities 7 into uncertificated holdings or despatch of certificates

N/A

N/A

N/A

N/A

N/A

17 April 2013

N/A

N/A

N/A

		Number	+Class
8 Number and <sup>+</sup> class of <sup>+</sup> securities quoted on <i>A</i> ( <i>including</i> the securities section 2 if applicable)	SX		Fully paid ordinary shares (ASX code: ATP)

Number and +class of all 9 +securities not quoted on ASX (including the securities in section 2 if applicable)

	Number	+Class
ll X n	32,582,005	Options exercisable at \$0.05 each, on or before 29 January 2014.
	950,000	Convertible notes
a	Dividends are paid	as authorised by

Dividend policy (in the case of a 10 trust, distribution policy) on the Directors. increased capital (interests)


# Part 2 - Bonus issue or pro rata issue

11	Is security holder approval N/A required?
	· · · · · · · · · · · · · · · · · · ·
12	Is the issue renounceable or non- renounceable?
13	Ratio in which the <sup>+</sup> securities will be offered
14	+Class of +securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating
	entitlements?
17	Policy for deciding entitlements in relation to fractions

18	Names of countries in which the entity has <sup>+</sup> security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	
	2	
25	If the issue is contingent on <sup>+</sup> security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	

<sup>+</sup> See chapter 19 for defined terms.

- 30 How do <sup>+</sup>security holders sell their entitlements *in full* through a broker?
- 31 How do <sup>+</sup>security holders sell part of their entitlements through a broker and accept for the balance?
- 32 How do <sup>+</sup>security holders dispose of their entitlements (except by sale through a broker)?
- 33 <sup>+</sup>Despatch date



#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities (*tick one*)
- (a) Securities described in Part 1
   NOTE only the fully paid ordinary shares should be quoted.
   (b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000
	1,001 - 5,000

1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37

A copy of any trust deed for the additional \*securities

### Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought	N/A	
39	Class of <sup>+</sup> securities for which quotation is sought		
40	Do the <sup>+</sup> securities rank equally in all respects from the date of allotment with an existing <sup>+</sup> class of quoted <sup>+</sup> securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they		
	<ul> <li>participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the securities in clause 38)	Number	+Class

#### Quotation agreement

<sup>+</sup> See chapter 19 for defined terms.

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Afterte .

Sign here:

...... Date: 19 April 2013 (<del>Director</del>/Company secretary)

Print name: SUSAN HUNTER

== == == == ==

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
<ul> <li>Add the following:</li> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate</li> </ul>	N/A
<i>line items</i> <b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	N/A
" <b>A</b> "	N/A

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	N/A	
<i>Step 3: Calculate "C", the amount 7.1 that has already been used</i>	of placement capacity under rule	
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	N/A	
Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	N/A	
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	N/A	
Note: number must be same as shown in Step 2		
Subtract "C"	N/A	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	N/A	
	[Note: this is the remaining placement capacity under rule 7.1]	

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule	
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	N/A	

<sup>+</sup> See chapter 19 for defined terms.

# Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10	N/A
Note: number must be same as shown in Step 2	
Subtract "E"	N/A
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	N/A
	Note: this is the remaining placement capacity under rule 7.1A